Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | HRH2 | P25021 | 7/20 | 0.39 |
| ▸ | HRH1 | P35367 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097292 | 0.93 | HRH3 (0.46) | HRH3KCNH2MAPT | |
| SCHEMBL10097289 | 0.92 | HRH3 (0.48) | HRH3KCNH2 | |
| SCHEMBL10252550 | 0.92 | HRH2 (0.42) | HRH3HRH2HRH1KCNH2EPHX2 | |
| SCHEMBL10253105 | 0.92 | MET (0.41) | HRH2HRH1EPHX2 | |
| SCHEMBL10097487 | 0.91 | POLB (0.48) | POLBMAPTEPHX2 | |
| SCHEMBL10095708 | 0.88 | HRH2 (0.45) | HRH3HRH2HRH1KCNH2POLB | |
| SCHEMBL10097413 | 0.86 | NPC1 (0.39) | MAPT | |
| SCHEMBL10097478 | 0.86 | EPHX2 (0.47) | HRH3KCNH2MAPTEPHX2 | |
| SCHEMBL10249721 | 0.85 | RAB9A (0.40) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL10097633 | 0.84 | EPHX2 (0.47) | HRH3POLBMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HRH3 976/4885HRH2 666/4885HRH1 1368/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | HRH3 3196/4885HRH2 2629/4885HRH1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.